188 related articles for article (PubMed ID: 11549067)
1. In vivo estimation of bioartificial liver with recombinant HepG2 cells using pigs with ischemic liver failure.
Enosawa S; Miyashita T; Fujita Y; Suzuki S; Amemiya H; Omasa T; Hiramatsu S; Suga K; Matsumura T
Cell Transplant; 2001; 10(4-5):429-33. PubMed ID: 11549067
[TBL] [Abstract][Full Text] [Related]
2. The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model.
Enosawa S; Miyashita T; Saito T; Omasa T; Matsumura T
Cell Transplant; 2006; 15(10):873-80. PubMed ID: 17299991
[TBL] [Abstract][Full Text] [Related]
3. Long-term culture of glutamine synthetase-transfected HepG2 cells in circulatory flow bioreactor for development of a bioartificial liver.
Enosawa S; Miyashita T; Suzuki S; Li XK; Tsunoda M; Amemiya H; Yamanaka M; Hiramatsu S; Tanimura N; Omasa T; Suga K; Matsumura T
Cell Transplant; 2000; 9(5):711-5. PubMed ID: 11144971
[TBL] [Abstract][Full Text] [Related]
4. Ammonia metabolism capacity of HepG2 cells with high expression of human glutamine synthetase.
Tang NH; Wang XQ; Li XJ; Chen YL
Hepatobiliary Pancreat Dis Int; 2008 Dec; 7(6):621-7. PubMed ID: 19073408
[TBL] [Abstract][Full Text] [Related]
5. Prolongation of survival of pigs with ischemic liver failure by treatment with a bioartificial liver using glutamine synthetase transfected recombinant HepG2.
Enosawa S; Miyashita T; Tanaka H; Li X; Suzuki S; Amemiya H; Omasa T; Suga K; Matsumura T
Transplant Proc; 2001; 33(1-2):1945-7. PubMed ID: 11267581
[No Abstract] [Full Text] [Related]
6. Development of a bioartificial liver with glutamine synthetase-transduced recombinant human hepatoblastoma cell line, HepG2.
Miyashita T; Enosawa S; Suzuki S; Tamura A; Tanaka H; Amemiya H; Matsumura T; Omasa T; Suga K; Aoki T; Koyanagi Y
Transplant Proc; 2000 Nov; 32(7):2355-8. PubMed ID: 11120198
[No Abstract] [Full Text] [Related]
7. Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs.
Li LJ; Du WB; Zhang YM; Li J; Pan XP; Chen JJ; Cao HC; Chen Y; Chen YM
J Hepatol; 2006 Feb; 44(2):317-24. PubMed ID: 16356580
[TBL] [Abstract][Full Text] [Related]
8. The bioreactor with CYP3A4- and glutamine synthetase-introduced HepG2 cells: treatment of hepatic failure dog with diazepam overdosage.
Wang N; Tsuruoka S; Yamamoto H; Enosawa S; Omasa T; Sata N; Matsumura T; Nagai H; Fujimura A
Artif Organs; 2005 Aug; 29(8):681-4. PubMed ID: 16048486
[TBL] [Abstract][Full Text] [Related]
9. Follow-up by one- and two-dimensional NMR of plasma from pigs with ischemia-induced acute liver failure treated with a bioartificial liver.
Tréhout D; Desille M; Doan BT; Mahler S; Frémond B; Mallédant Y; Campion JP; Desbois J; Beloeil JC; de Certaines J; Clément B
NMR Biomed; 2002 Oct; 15(6):393-403. PubMed ID: 12357553
[TBL] [Abstract][Full Text] [Related]
10. Expression of glutamine synthetase and carbamoylphosphate synthetase i in a bioartificial liver: markers for the development of zonation in vitro.
Poyck PP; Hoekstra R; Vermeulen JL; van Wijk AC; Chamuleau RA; Hakvoort TB; van Gulik TM; Lamers WH
Cells Tissues Organs; 2008; 188(3):259-69. PubMed ID: 18354250
[TBL] [Abstract][Full Text] [Related]
11. Alginate-encapsulated HepG2 cells in a fluidized bed bioreactor maintain function in human liver failure plasma.
Coward SM; Legallais C; David B; Thomas M; Foo Y; Mavri-Damelin D; Hodgson HJ; Selden C
Artif Organs; 2009 Dec; 33(12):1117-26. PubMed ID: 20078562
[TBL] [Abstract][Full Text] [Related]
12. The newly established human hepatocyte cell line: application for the bioartificial liver.
Harimoto N; Taketomi A; Kitagawa D; Kuroda Y; Itoh S; Gion T; Tanaka S; Shirabe K; Shimada M; Maehara Y
J Hepatol; 2005 Apr; 42(4):557-64. PubMed ID: 15763342
[TBL] [Abstract][Full Text] [Related]
13. [Metabolic evaluation of cultured porcine hepatocyte monolayers in human plasma from hepatic failure patients--basic study on development of a bioreactor in hybrid artificial liver].
Matsue H
Hokkaido Igaku Zasshi; 1996 Jul; 71(4):543-55. PubMed ID: 8809577
[TBL] [Abstract][Full Text] [Related]
14. Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system.
Omasa T; Kim K; Hiramatsu S; Katakura Y; Kishimoto M; Enosawa S; Ohtake H
Biotechnol Prog; 2005; 21(1):161-7. PubMed ID: 15903254
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of nonwoven fabric bioreactor immobilized with porcine hepatocytes for ex vivo xenogeneic perfusion treatment of liver failure in dogs.
Naruse K; Sakai Y; Lei G; Sakamoto Y; Kobayashi T; Puliatti C; Aronica G; Morale W; Leone F; Qiang S; Ming SG; Ming S; Li Z; Chang SJ; Suzuki M; Makuuchi M
Artif Organs; 2001 Apr; 25(4):273-80. PubMed ID: 11318756
[TBL] [Abstract][Full Text] [Related]
16. Standardization of ischemic hepatic failure in pigs as a model for bioartificial liver assessment.
Miyashita T; Enosawa S; Tanaka H; Tamura A; Amemiya H; Aoki T; Koyanagi Y; Suzuki S
Surg Today; 2003; 33(10):743-50. PubMed ID: 14513321
[TBL] [Abstract][Full Text] [Related]
17. Use of ultrathin shell microcapsules of hepatocytes in bioartificial liver-assist device.
Sun T; Chan ML; Zhou Y; Xu X; Zhang J; Lao X; Wang X; Quek CH; Chen JP; Leong KW; Yu H
Tissue Eng; 2003; 9 Suppl 1():S65-75. PubMed ID: 14511471
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver.
Poyck PP; van Wijk AC; van der Hoeven TV; de Waart DR; Chamuleau RA; van Gulik TM; Oude Elferink RP; Hoekstra R
J Hepatol; 2008 Feb; 48(2):266-75. PubMed ID: 18093687
[TBL] [Abstract][Full Text] [Related]
19. Significant contribution of liver nonparenchymal cells to metabolism of ammonia and lactate and cocultivation augments the functions of a bioartificial liver.
Nedredal GI; Elvevold K; Ytrebø LM; Fuskevåg OM; Pettersen I; Bertheussen K; Langbakk B; Smedsrød B; Revhaug A
Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G75-83. PubMed ID: 17363468
[TBL] [Abstract][Full Text] [Related]
20. Significant survival prolongation in pigs with fulminant hepatic failure treated with a novel microgravity-based bioartificial liver.
Hochleitner B; Hengster P; Bucher H; Ladurner R; Schneeberger S; Krismer A; Kleinsasser A; Barnas U; Klima G; Margreiter R
Artif Organs; 2006 Dec; 30(12):906-14. PubMed ID: 17181831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
